Following an extensive review of its manufacturing network globally, Pfizer Inc (“Pfizer”) has taken a decision to consolidate its manufacturing operations. In support of this program, PharmaBioSource and DTZ are currently working with Pfizer Cork Limited (“PCL”), a subsidiary of Pfizer, on the sale of its Irish based Dunkettle Active Pharmaceutical Ingredient (API) Manufacturing Facility.

Project Dunkettle provides an opportunity to acquire a fully operational and licensed API and pharmaceutical intermediate manufacturing site with FDA and EMEA approvals as well as approvals to supply products to over 120 markets including Japan and Australia. The manufacturing site encompasses the following:

• High Containment Facilities capable of handling potent and cytotoxic compounds: five EMEA and FDA approved flexible, automated equipment trains with over 5,500 L of containment synthesis capacity with occupational exposure levels (OELs) of less than 1 µg/ m3. Equipment sizes ranging from 100 L to 600 L.
  
  
• Mid Scale API Manufacturing Facility: consisting of seven flexible equipment trains totalling over 30,000 L of capacity. The production facilities have a total of 21 reactors with capacities ranging from 250 to 4,000 L which currently produce batch sizes ranging from 120g to 300kgs. The facilities have been approved by the FDA and EMEA to produce APIs and complex pharmaceutical intermediates. The facilities have potent material handling capability using glove box and flexible containment technology.
  
  
• Kilo and Gram Scale Units: The site has a recently commissioned state-of-the- art modular designed and automated kilo scale manufacturing unit. This has 3* 80l glass reactor units, each with full unit operations flexibility, located within fume hoods. This unit can be used for small volume potent APIs, or for manufacture of developmental or clinical trial lots. There is also a gram scale unit with 30 to 60 L reactors with similar capability.
  
  
• Laboratory and Development Facilities: a modern well equipped laboratory facility (providing QA as well as extensive technical process development and new product introduction capabilities).
  
  
• Infrastructure and Support Facilities: in addition to modern, recently built warehousing facilities and normal support services including utilities, waste water treatment, solvent tank farm, and administration offices.
  
  
• Additional Parcels: There is an opportunity to acquire additional parcels of land, one of which contains a refurbished office facility as well as ample expansion space.